CAITLIN MATSUMOTO: Open Payments
NPI 1295104602 · UPLAND, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,141 in 123 payments from 37 companies in 2025. Trend: 2023 $3,172 · 2024 $3,045 · 2025 $3,141
Food & beverage: $3,141
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 21 | $611 |
| Genentech USA, Inc. | 16 | $293 |
| GlaxoSmithKline, LLC. | 10 | $230 |
| Regeneron Healthcare Solutions, Inc. | 6 | $185 |
| Novartis Pharmaceuticals Corporation | 7 | $155 |
| Daiichi Sankyo Inc. | 5 | $125 |
| Incyte Corporation | 4 | $98 |
| Rigel Pharmaceuticals, Inc. | 4 | $91 |
| PFIZER INC. | 4 | $84 |
| Merck Sharp & Dohme LLC | 3 | $84 |
Products named: ENHERTU, LYNPARZA, LIBTAYO, OJJAARA, Itovebi, TAVALISSE, SCEMBLIX, KEYTRUDA.
Industry payments across CA — which companies pay providers there.
